CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress
Provides interested parties the ability to ask questions and submit topics for future videos
Access the AIM CEO Corner Here!
OCALA, Fla., March 07, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the launch of its CEO Corner featuring Thomas K Equels, M.S., J.D., Executive Vice Chairman, Chief Executive Officer & President of AIM ImmunoTech. The CEO Corner platform is intended to provide additional and in-depth perspective to press releases, corporate developments and development pipeline progress.
“Keeping our stakeholders well informed is absolutely essential to the future success of AIM ImmunoTech,” states Equels. “CEO Corner is a new way for us to connect directly with both current and potential stockholders. CEO Corner segments will provide expanded perspective on press releases, clinical trials and other corporate advancements as we continue to push forward with our development pipeline. We believe in the future of Ampligen and are dedicated to growing value for all stakeholders.”
The CEO Corner is now accessible on the Company’s website here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on Twitter, LinkedIn, and Facebook.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bf36df6a-66a3-4b6b-9b53-57c074b48a66
Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
